Collegium Pharmaceutical, Inc. COLL Segment — Net Income (Loss) Attributable to Parent
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — net income (loss) attributable to parent of $14.5M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent increased by 499.8% year-over-year, from $2.42M to $14.5M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — net income (loss) attributable to parent has grown at a 36.0% compound annual growth rate (CAGR), from -$25M to $62.87M.
- What does segment — net income (loss) attributable to parent mean?
- This metric represents the final bottom-line profitability of the business segment after accounting for all operating expenses, interest, taxes, and non-operating items. It serves as the primary indicator of the segment's financial health and its ability to generate value for the parent company's shareholders. A consistent positive trend indicates strong operational execution and effective cost management.